Moderna (WBO:MRNA) Pre-Tax Income : €-3,670 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Moderna Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Moderna's pretax income for the three months ended in Dec. 2023 was €64 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €-3,670 Mil. Moderna's pretax margin was 2.49%.

During the past 8 years, Moderna's highest Pretax Margin was 74.90%. The lowest was -1072.92%. And the median was -178.28%.

Moderna Pre-Tax Income Historical Data

The historical data trend for Moderna's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Pre-Tax Income Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-463.50

-611.57

11,757.23

9,038.80

-3,614.81

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															1,562.32	-284.87	-1,614.33	-1,834.65	64.19

Competitive Comparison of Moderna's Pre-Tax Income

For the Biotechnology subindustry, Moderna's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Moderna's Pre-Tax Income falls into.

Moderna Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Moderna's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3887.163	+	-78.862	+	-34.846	+	386.057	+	4.5474735088646E-13
	=	-3,615

Moderna's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	5.502	+	-30.261	+	-5.502	+	94.451	+	0
	=	64

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3,670 Mil.

Moderna (WBO:MRNA) Pre-Tax Income Explanation

Moderna's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	64.19	/	2579.521
	=	2.49%

During the past 8 years, Moderna's highest Pretax Margin was 74.90%. The lowest was -1072.92%. And the median was -178.28%.

Moderna Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Moderna's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (WBO:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.